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Rotavirus is the most common cause of gastroenteritis among children under 5 years of age leading to 
~200,000 deaths in 2013.1 Rotavirus-attributed mortality can be significantly reduced by promoting global 
implementation of rotavirus vaccination by vaccine dosage cost reduction and optimizing vaccine efficacy in low-
resource countries. Furthermore, a rotavirus vaccine administered at birth could prevent neonatal mortality and 
reduce the risk of intussusception 2. An oral human neonatal rotavirus vaccine candidate (RV3-BB) has been 
developed from the human neonatal rotavirus strain RV3 (G3P[6]) 2 , and a recently published Phase IIb clinical 
trial showed RV3-BB was efficacious in preventing severe  rotavirus gastroenteritis via a neonatal or infant 
schedule in Indonesia2.  The overall goals of this project are to develop and implement commercially viable bulk 
and drug product manufacturing processes of a stable liquid formulation for oral delivery (without pre-
neutralization) that is affordable in the developing world (Fig. 1). The consortium working on this program is 
sponsored by the Bill and Melinda Gates Foundation between Batavia Biosciences, Murdoch Children’s 
Research Institute, BioFarma, and The University of Kansas.  
 The formulation goals are to develop a refrigerator stable (i.e., 2 years, 2-8⁰C) liquid 
formulation, based on the same RV3 strain, with no requirement to pre-neutralize gastric 
acid during administration. Analytical characterization of virus bulks and purified virus 
was performed in terms of potency, size, concentration, morphology, and physical 
stability. FFA and qPCR potency assays were developed and implemented for 
formulation development and stability evaluation. Optimization of various formulation 
parameters including pH and excipients to stabilize RV3 against various environmental 
stresses (thermal, agitation, and freeze-thaw) was performed.  Excipient screening was 
first performed to evaluate the effect of individual excipients, followed by evaluation of 
various combinations. Rotavirus vaccines present a unique formulation challenge 
requiring careful balance of stabilizing the virus against low pH environments during oral 
delivery vs. long term storage stability. Accelerated and real-time stability studies with 
RV3 candidate formulations are in progress to elucidate the most stable formulation(s) 
that meet the aforementioned criteria (i.e., 2 year stability at 2-8⁰C and withstand acid 
induced potency loss). Stability modelling studies based on extrapolation of accelerated 
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